Baxter International Inc.

The Rockefeller University

North American Vaccine, Inc.

Baxter Healthcare Sa

Blake Laboratories, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

Bacter Healthcare S.a.

Immunogon Associates

Pfizer Ireland Pharmaceuticals

Milan S Blake

Joseph Y Tai

Francis Michon

Shu-Mei Liang

Jeffrey K Pullen

John A Bogdan, Jr

Javier Nazario-Larrieu

Lucjan J Hronowski

Huilin L Qi

Emil Claus Gotschlich

Dennis J Kopecko

John B Zabriskie

Manuel Osorio

Gregory J Russell-Jones

Siba Bhattacharyya

Peter C Fusco

Iver Heron

Chandrakant P Giri

Thomas Soper

Lee Mark Wetzler

John Michael Koomey

The invention is related to intracellularly induced bacterial DNA promoters and vaccines against

DNA promoters and anthrax vaccines

Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin expression inhibitor binding compounds, culture media having reduced concentrations of toxin inhibitor metabolic precursors and genetically modified toxogenic bacteria lacking enzymes required to metabolize the toxin inhibitor metabolic precursors.

Method for the production of bacterial toxins

This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.

Group A streptococcal polysaccharide immunogenic compositions and methods

This invention relates to mutants of Neisseria useful for vaccine preparation. Specifically this invention relates to mutants of Neisseria containing mutations in a major outer membrane protein gene such that no immunologically functional polypeptides encoded by said gene are produced. More specifically, the invention relates to a mutant strain of having a mutation of the PIII gene and to vaccines derived therefrom.

Neisserial vaccine free of immunologically functional PIII or class 4 proteins

Disclosed is an type b polysaccharide-meningococcal outer membrane protein conjugate, pharmaceutical compositions thereof, and the use thereof to induce an immune response to in an animal.

Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide

Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide

A-X,X,X,X,X,X,X,X,X,X,X,X,-B, wherein A represents amino acid residues 38-201 of SEQ ID NO: 2, B represents a sequence starting from amino acid 214 of SEQ ID NO: 2 and terminating at an amino acid between residues 1131 and 1164, inclusive, of SEQ ID NO: 2, and X,through X,are each selected independently from Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, a bond, or a wild-type amino acid as found at a corresponding position of residues 202-213 of SEQ ID NO: 2, with the proviso that at least one of X,through X,, inclusive, is other than the wild type amino acid found at the corresponding position of SEQ ID NO: 2. The LPXTG motif, as found in the native protein at amino acid residues corresponding to residues 1132-1136 of SEQ ID NO: 2, may be deleted in the sequence of the mutant C&bgr; protein. The mutant C&bgr; protein is conjugated to a streptococcal capsular polysacharide in a vaccine composition, also having an acceptable pharmaceutical carrier, for use in a method of including an immune response in an animal. Nucleic acid molecules encoding the mutant protein, vectors containing these molecules, and host cells transformed therewith are also disclosed.

Non-IgA Fc binding forms of the group B streptococcal &bgr; antigens

A procedure to isolate large quantities of capsular poly saccharides (CPS) from culture supernatants as well as bacterial cells of gram-negative and gram-positive bacteria using base extraction is described. The procedure is simple, rapid, reproducible and applicable to a variety of bacterial species. The method also yields novel CPS characterized by their lack of covalent attachment to extraneous peptidoglycan. Vaccines and methods of immunization against bacterial infection using the CPS obtained by the process of the invention are also disclosed.

Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines

The present invention relates, in general, to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b (Hib-P2) and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b or fusion protein thereof in E. coli wherein the Hib-P2 protein or fusion protein comprises more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of Hib-P2 protein and fusion protein thereof.

Method for the high level expression, purification and refolding of the

Disclosed and claimed is a novel inexpensive and efficient method for the early detection of HIV infection in babies. The method utilizes a unique IgA capture ELISA procedure for detection of HIV-specific antibodies.

Method for early detection of HIV infection in babies

Growing community of inventors

New York, NY, United States of America

Milan S Blake